BioNTech intends to conduct a pilot study of a novel malaria vaccine ‘by 2022.’
BioNTech, a German pharmaceutical company, intends to produce its first malaria vaccine and start clinical trials next year.
The aggressive timeline is possible because of the MRNA technology that was utilized to create the Pfizer and Moderna coronavirus vaccines in less than a year.
Mosquirix, the only licenced malaria vaccine, took over 30 years to develop by scientists at GlaxoSmithKline.
Malaria claims about 400,000 lives each year, most of them youngsters in Sub-Saharan Africa.
Apart from vaccinations and tablets, countries such as Malawi, Tanzania, and Kenya utilize drones to locate mosquito breeding sites and destroy larvae prior to hatching.